Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash ...
CEO Jacqueline Shea highlighted that "these are very exciting times for Inovio with our first BLA for INO-3107 as a potential treatment for adults with recurrent respiratory papillomatosis or RRP, ...
Inovio Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.31, expectations were $-0.358. Operator: Good afternoon, ladies and gentlemen, and welcome to the Inovio Fourth Quarter and ...
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2025 Earnings Call Transcript March 12, 2026 Inovio Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.31, expectations were $-0.358.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results